19 June 2024 - final results
The AIM-listed pharmaceutical company has finally produced its results for the year to 31 December after a number of delays caused by the auditors. These have shown a considerable write-off of non-tangible assets of £79.3m as the company takes a more cautious view of such valuations. It is imprtant to point out that these are non-cash adjustments and therefore have no impact on the company's cash position. The year saw a stronger second half as previously highlighted resulting in record revenues for the year of over £180m (2022: £167m . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
